Shares of Solventum Corporation (NYSE:SOLV – Get Free Report) have earned an average rating of “Moderate Buy” from the twelve brokerages that are covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $93.70.
A number of brokerages recently weighed in on SOLV. Mizuho set a $100.00 price objective on shares of Solventum and gave the company an “outperform” rating in a research report on Tuesday, January 20th. Zacks Research cut shares of Solventum from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. BTIG Research restated a “buy” rating and issued a $100.00 target price on shares of Solventum in a research note on Friday, February 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Finally, Stifel Nicolaus increased their price target on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th.
Read Our Latest Stock Analysis on SOLV
Institutional Investors Weigh In On Solventum
Solventum Stock Performance
Solventum stock opened at $67.57 on Wednesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. Solventum has a 12 month low of $60.70 and a 12 month high of $88.20. The company has a fifty day moving average price of $77.14 and a two-hundred day moving average price of $76.13. The company has a market cap of $11.72 billion, a PE ratio of 7.62, a P/E/G ratio of 1.12 and a beta of 0.40.
Solventum (NYSE:SOLV – Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.96 billion. During the same period in the prior year, the company earned $1.41 earnings per share. The firm’s revenue was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Research analysts expect that Solventum will post 6.58 earnings per share for the current year.
Solventum declared that its board has initiated a share buyback plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 7.5% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
Read More
- Five stocks we like better than Solventum
- The gold chart Wall Street is terrified of…
- What a Former CIA Agent Knows About the Coming Collapse
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
